Biogen Inc at Cowen Health Care Conference Transcript
Good morning, and welcome once again to Cowen & Company's 39th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to introduce one of our first companies, Biogen, one of the luminaries in the industry. Then we're going to do a fireside chat with CEO, Michel Vounatsos.
Michel, do you want to start with maybe some opening remarks?
Certainly. So good morning, everybody. And thank you for having Biogen and me.
We may make some forward-looking statements, so I refer you back to our SEC filing.
2018 was a very good year. Top line double digit. Bottom line, even stronger. And I would say more importantly, we have enriched and advanced our pipeline portfolio very well, beyond aducanumab. But for aducanumab also, we increased the POS based on the results of BAN2401. And we are very encouraged by the results of our ASO SOD1 program,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
